Top tier leap based on 4E…Samsung Biologics CEO John Lim Announces Strategy at JPMorgan Healthcare Conference
Jan 15, 2025
|
President John Lim said, "Despite the challenging business environment in 2024, Samsung Biologics maintained strong growth through 4E""We will continue to grow by completing the 5th plant in 2025 and starting the production of antibodies and drug conjugates (ADC)."."
4E refers to ▲ Customer Excellence, ▲ Operational Excellence, ▲ Quality Excellence, and ▲ Excellent Employee Competency as values that Samsung BioLogics should pursue. Based on this, Samsung Biologics plans to continue its growth by speeding up its three-axis expansion strategies: production capacity, business portfolio, and geographic base.
Samsung Biologics held a corporate presentation at the main venue of JPMHC, the world's largest pharmaceutical and bio investment event held in January every year. The Grand Ballroom is a stage that can only be presented by 27 selected companies among 550 officially invited companies. Following last year, the order of presentation was also allocated for the second day of events such as global big pharma such as GlaxoSmithKline (GSK), Eli Lilly, and AstraZeneca (AZ).
CEO John Lim said, "In 2024, orders exceeded KRW 5 trillion, and cumulative orders have exceeded USD 17.6 billion so far."In 2024, annual sales are also expected to increase by 15-20% year-on-year, which is about 15 times higher than sales in 2016 (294.6 billion won)," he explained. "To strengthen future growth engines, we will continue to make preemptive and bold investments in line with Samsung's bio business vision and roadmap."We will do our best in 2025 to realize the 'Vision 2030', which is to become a top tier bio company in the industry based on the '4E'," he said.
This article was translated by Naver AI translator.
